BioCryst Flu Treatment’s Success May Hinge On Government Contract
This article was originally published in The Pink Sheet Daily
Executive Summary
Rapivab (peramivir) is company’s first FDA approval, but market opportunity is small; some analysts predict firm will focus resources on hereditary angioedema development programs.
You may also be interested in...
Better Together: BioCryst, Idera Merge To Improve Rare Disease Position
New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.
FDA Approval Round Up: Keytruda, Opdivo Add Claims
Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.